E Fund Management Co. Ltd. Sells 7,498 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

E Fund Management Co. Ltd. lowered its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 21.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,734 shares of the biopharmaceutical company’s stock after selling 7,498 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Amicus Therapeutics were worth $275,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Comerica Bank raised its stake in Amicus Therapeutics by 0.8% during the 4th quarter. Comerica Bank now owns 103,418 shares of the biopharmaceutical company’s stock valued at $1,468,000 after purchasing an additional 774 shares during the period. Franklin Resources Inc. raised its stake in Amicus Therapeutics by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 54,943 shares of the biopharmaceutical company’s stock valued at $780,000 after purchasing an additional 1,258 shares during the period. American International Group Inc. raised its stake in Amicus Therapeutics by 0.9% during the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock valued at $2,004,000 after purchasing an additional 1,298 shares during the period. Arizona State Retirement System raised its stake in Amicus Therapeutics by 2.6% during the 2nd quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after purchasing an additional 1,577 shares during the period. Finally, Principal Financial Group Inc. raised its stake in Amicus Therapeutics by 1.1% during the 2nd quarter. Principal Financial Group Inc. now owns 240,813 shares of the biopharmaceutical company’s stock valued at $2,389,000 after purchasing an additional 2,737 shares during the period.

Insider Transactions at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 6,100 shares of the company’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total value of $87,825.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $10,382,718.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bradley L. Campbell sold 6,100 shares of the company’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,100 shares of company stock worth $226,375. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock opened at $10.91 on Thursday. The stock has a market cap of $3.23 billion, a price-to-earnings ratio of -22.27 and a beta of 0.69. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75. The stock has a 50 day moving average price of $11.00 and a 200-day moving average price of $10.74. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). The firm had revenue of $126.67 million during the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The company’s quarterly revenue was up 34.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.15) EPS. Equities analysts expect that Amicus Therapeutics, Inc. will post -0.08 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on FOLD shares. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Jefferies Financial Group started coverage on Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price target for the company. Wells Fargo & Company started coverage on Amicus Therapeutics in a report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price target for the company. Finally, JPMorgan Chase & Co. cut their price target on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.